Updated on 2024/12/27

写真a

 
IMAMURA Masaru
 
Organization
Academic Assembly Institute of Medicine and Dentistry IGAKU KEIRETU Associate Professor
Faculty of Medicine School of Medicine Associate Professor
Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Homeostatic Regulation and Developments Associate Professor
Title
Associate Professor
External link

Degree

  • 医学 ( 2008.3   新潟大学 )

Research History

  • Niigata University   Institute of Medicine and Dentistry, Academic Assembly   Associate Professor

    2024.4

  • Niigata University   Homeostatic Regulation and Developments, Biological Functions and Medical Control, Graduate School of Medical and Dental Sciences   Associate Professor

    2024.4

  • Niigata University   School of Medicine, Faculty of Medicine   Associate Professor

    2024.4

  • Niigata University   University Medical and Dental Hospital Pediatrics   Lecturer

    2016.4 - 2024.3

  • Niigata University   Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Homeostatic Regulation and Developments   Assistant Professor

    2015.5 - 2016.3

  • Niigata University   University Medical and Dental Hospital Pediatrics   Specially Appointed Assistant Professor

    2014.4 - 2015.4

  • Niigata University   University Medical and Dental Hospital Pediatrics   Specially Appointed Assistant Professor

    2009.4 - 2011.6

▶ display all

 

Papers

  • Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.

    Yugo Kawakami, Masaru Imamura, Chihaya Imai

    International journal of hematology   119 ( 5 )   479 - 480   2024.5

     More details

  • Regression of kaposiform lymphangiomatosis and chronic disseminated intravascular coagulation after inhaled budesonide-formoterol treatment. International journal

    Masaru Imamura, Chansu Shin, Michio Ozeki, Kentaro Matsuoka, Akihiko Saitoh, Chihaya Imai

    Pediatric blood & cancer   71 ( 4 )   e30907   2024.4

     More details

    Language:English  

    DOI: 10.1002/pbc.30907

    PubMed

    researchmap

  • Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. International journal

    Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, Makoto Oishi

    Current oncology (Toronto, Ont.)   31 ( 4 )   1831 - 1838   2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Molecular analysis of the growing teratoma syndrome has not been extensively studied. Here, we report a 14-year-old boy with a growing mass during treatment for a mixed germ cell tumor of the pineal region. Tumor markers were negative; thus, growing teratoma syndrome was suspected. A radical resection via the occipital transtentorial approach was performed, and histopathological examination revealed a teratoma with malignant features. Methylation classifier analysis confirmed the diagnosis of teratoma, and DMRT1 loss and 12p gain were identified by copy number variation analysis, potentially elucidating the cause of growth and malignant transformation of the teratoma. The patient remains in remission after intense chemoradiation treatment as a high-risk germ cell tumor.

    DOI: 10.3390/curroncol31040138

    PubMed

    researchmap

  • がんゲノム医療がもたらす小児脳腫瘍の展開 TP53変異を有する脈絡叢癌培養細胞株の樹立およびマルチオミクス解析

    棗田 学, 温 城太郎, 塚本 佳広, 岡田 正康, 大石 誠, 久保 暢大, 申 将守, 今村 勝, 今井 千速, エルナガール・シャヘンダ, 藤井 幸彦

    小児の脳神経   48 ( 2 )   156 - 156   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本小児神経外科学会  

    researchmap

  • NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma

    Yudai Murayama, Yasushi Kasahara, Nobuhiro Kubo, Chansu Shin, Masaru Imamura, Naoki Oike, Takashi Ariizumi, Akihiko Saitoh, Minori Baba, Tomohiro Miyazaki, Yuko Suzuki, Yiwei Ling, Shujiro Okuda, Keichiro Mihara, Akira Ogose, Hiroyuki Kawashima, Chihaya Imai

    Translational Oncology   25   101521 - 101521   2022.11

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.tranon.2022.101521

    researchmap

  • BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis. International journal

    Ko Kudo, Tsutomu Toki, Rika Kanezaki, Tatsuhiko Tanaka, Takuya Kamio, Tomohiko Sato, Shinya Sasaki, Masaru Imamura, Chihaya Imai, Kumiko Ando, Harumi Kakuda, Takehiko Doi, Hiroshi Kawaguchi, Masahiro Irie, Yoji Sasahara, Akihiro Tamura, Daiichiro Hasegawa, Yosuke Itakura, Kenichiro Watanabe, Kenichi Sakamoto, Yoko Shioda, Motohiro Kato, Kazuko Kudo, Reiji Fukano, Atsushi Sato, Hiroshi Yagasaki, Hirokazu Kanegane, Itaru Kato, Katsutsugu Umeda, Souichi Adachi, Tatsuki Kataoka, Akira Kurose, Atsuko Nakazawa, Kiminori Terui, Etsuro Ito

    Haematologica   107 ( 7 )   1719 - 1725   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3324/haematol.2021.279857

    PubMed

    researchmap

  • Newly diagnosed ETV6-RUNX1-positive B-acute lymphoblastic leukemia localized to the left pelvic bone marrow.

    Minori Baba, Masaru Imamura, Chihaya Imai

    International journal of hematology   115 ( 2 )   151 - 152   2022.2

     More details

  • Drug-induced panniculitis in a child with acute lymphoblastic leukemia. International journal

    Haruko Iwabuchi, Takayuki Takachi, Nobuhiro Kubo, Masaru Imamura, Hajime Umezu, Akihiko Saitoh, Chihaya Imai

    Pediatric blood & cancer   69 ( 5 )   e29501   2021.12

     More details

    Language:English  

    DOI: 10.1002/pbc.29501

    PubMed

    researchmap

  • Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. International journal

    Yudai Murayama, Hiroyuki Kawashima, Nobuhiro Kubo, Chansu Shin, Yasushi Kasahara, Masaru Imamura, Naoki Oike, Takashi Ariizumi, Akihiko Saitoh, Keichiro Mihara, Hajime Umezu, Akira Ogose, Chihaya Imai

    Translational oncology   14 ( 12 )   101227 - 101227   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Synovial sarcoma is a rare malignant soft-tissue tumor that is prevalent in adolescents and young adults, and poor prognosis has been reported in patients with metastatic lesions. Chimeric antigen receptor (CAR) T-cell therapy is an emerging novel therapy for solid tumors; however, its application in synovial sarcoma has not yet been explored. METHODS: A novel human epidermal growth factor receptor 2 (HER2)-targeted CAR containing scFv-FRP5, CD8α hinge and transmembrane domains as well as 4-1BB costimulatory and CD3ζ signaling domains was developed. Three synovial sarcoma cell lines that expressed the fusion transcript SS18-SSX1/2/4 were used in the study. Cytokine secretion assay, cytotoxicity assay, and real-time cell analysis experiments were conducted to confirm the function of T cells transduced with the CAR gene. RESULTS: High cell-surface expression of HER2 was observed in all the cell lines. HER2-targeted/4-1BB-costimulated CAR T cells specifically recognized the synovial sarcoma cells, secreted interferon gamma and tumor necrosis factor alpha, and exerted cytotoxic effects in these cells. CONCLUSION: To the best of our knowledge, this is the first study to indicate that HER2-targeted CAR T cells are directly effective against molecularly defined synovial sarcoma cells. Furthermore, our findings might set the basis for developing improved CAR T cell-based therapies for chemo-refractory or relapsed synovial sarcoma.

    DOI: 10.1016/j.tranon.2021.101227

    PubMed

    researchmap

  • 抗体刺激と複合サイトカインによるヒトNK細胞の体外増幅(Ex vivo expansion of primary human NK cells using antibody-based stimulus and multiple cytokines)

    久保 暢大, 馬場 みのり, 申 将守, 細貝 亮介, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    日本血液学会学術集会   83回   OS1 - 2   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 左腸骨に限局したETV6-RUNX1陽性前駆B細胞性急性リンパ性白血病の一例(ETV6-RUNX1-positive B-acute lymphoblastic leukemia localizing in the left iliac bone: a case report)

    馬場 みのり, 今村 勝, 申 将守, 細貝 亮介, 岩渕 晴子, 齋藤 昭彦, 今井 千速

    日本血液学会学術集会   83回   PS - 3   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 肢端紅痛症で発症し、無症候性後天性フォンウィルブランド症候群を合併した本態性血小板血症の小児例

    村山 ゆり恵, 田屋 光将, 申 将守, 馬場 みのり, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    小児科臨床   74 ( 5 )   553 - 558   2021.5

     More details

    Language:Japanese   Publisher:(株)日本小児医事出版社  

    症例は12歳男児。両側の手指、足趾、手掌の肢端紅痛症で発症し、99.7万/μLの血小板増多を認め、骨髄所見やJAK2変異陽性から、本態性血小板血症(essential thrombocythemia;ET)と診断した。肢端紅痛症に対し少量アスピリン投与を開始したところ、症状は速やかに消失した。アスピリン投与開始後、血小板数は140万/μLへと増加傾向を示したため、後天性フォンウィルブランド症候群の検索を行い、合併が判明した。ガイドラインではアスピリンは原則禁忌となり細胞減少療法の適応となるが、本症例では出血症状は皆無であり、年齢や殺細胞薬使用に伴う白血病転化リスクを考慮した結果、アスピリン療法単独を継続し、6年経過した現在まで安全に管理できている。小児ETは非常に稀な疾患であり、治療アルゴリズムは確立していない。小児期特有の問題を加味した診療指針が作成されることが望まれる。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J00643&link_issn=&doc_id=20210427420011&doc_link_id=%2Fag1snrsd%2F2021%2F007405%2F012%2F0553-0558%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fag1snrsd%2F2021%2F007405%2F012%2F0553-0558%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • ランゲルハンス細胞組織球症との鑑別を要した播種性BCG感染症を合併したIFN-γR1部分欠損症

    原田 瑞生, 久保 暢大, 高地 貴行, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 梅津 哉, 山中 崇之, 今井 耕輔, 岡田 賢, 今井 千速

    日本小児血液・がん学会雑誌   57 ( 3 )   309 - 313   2020.11

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    症例は9ヵ月男児.繰り返す発熱,腋窩リンパ節腫大,全身の膿疱性皮疹を主訴に当院に紹介された.当初,前頭骨の骨融解像,臨床像,sIL-2R異常高値からランゲルハンス組織球症との鑑別を要し,皮膚生検を施行したが確定診断に至らず,腋窩リンパ節生検を施行した.生検組織からBCG菌が同定され,播種性BCG感染症と診断した.皮膚生検ではBCG菌は検出されず,BCG菌への過敏性反応による結核疹と考えられた.重症細菌感染,ウイルス感染の既往はなく,メンデル遺伝型マイコバクテリア易感染症を疑い精査した結果,IFNGR1遺伝子の既知のde-novoヘテロ変異が同定され,IFN-γR1部分欠損症と診断した.抗結核薬イソニアジド,リファンピシンの2剤による治療で症状は速やかに軽快した.18ヵ月間内服を継続し,終了後半年の現在も再燃なく経過している.ランゲルハンス組織球症として非典型的な皮疹や経過の場合にはBCG感染症を考える必要がある.(著者抄録)

    researchmap

  • 高リスク神経芽腫の治療後に発症した治療関連KMT2A再構成陽性急性リンパ性白血病

    馬場 みのり, 今村 勝, 申 将守, 笠原 靖史, 岩渕 晴子, 斎藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   57 ( 4 )   333 - 333   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. International journal

    Natasha Vinanica, Arthur Yong, Desmond Wong, Yi Tian Png, See Voon Seow, Masaru Imamura, Dario Campana

    Blood   135 ( 9 )   668 - 679   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    In adoptive T-cell immunotherapy of cancer, expansion and persistence of effector cells is a key determinant of response. We tested whether T lymphocytes could be rendered sensitive to erythropoietin (Epo) through ectopic expression of its wild-type receptor or a truncated form (EpoRm), which augments Epo signaling in erythrocyte progenitors. Both receptors could be expressed in human T lymphocytes; Epo ligation induced STAT5 phosphorylation, which was abrogated by nontoxic concentrations of the JAK1/2 inhibitor ruxolitinib. EpoRm had higher expression and triggered more potent stimulation than its wild-type counterpart, including superior T-cell survival and proliferation. Using a bicistronic vector, we expressed EpoRm together with an anti-CD19-41BB-CD3ζ chimeric antigen receptor (CAR), while maintaining the functions of each receptor. In the presence of Epo, EpoRm-CAR T cells had greater ex vivo expansion than CAR T cells and killed CD19+ leukemic cells more effectively in long-term cultures. In immunodeficient mice, physiologic levels of murine Epo were sufficient to preferentially expand EpoRm-CAR T cells, yielding a significantly higher antileukemic activity. Thus, outfitting adoptive T cells with EpoRm should yield greater effector-to-target ratios with a smaller number of infused cells; Epo or ruxolitinib administration could be used to adjust their levels postinfusion, maximizing antitumor activity and minimizing toxicity.

    DOI: 10.1182/blood.2019001645

    PubMed

    researchmap

  • Spontaneous remission of infant acute myeloid leukemia with a novel four-way translocation. International journal

    Nobuhiro Kubo, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai

    Pediatric blood & cancer   67 ( 2 )   e28052   2020.2

     More details

    Language:English  

    DOI: 10.1002/pbc.28052

    PubMed

    researchmap

  • Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity. International journal

    Yasushi Kasahara, Chansu Shin, Nobuhiro Kubo, Keichiro Mihara, Haruko Iwabuchi, Takayuki Takachi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai

    Clinical & translational immunology   9 ( 7 )   e1147   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Objectives: One of the reasons as to why chimeric antigen receptors (CAR)-T cell therapy for malignancies other than CD19- or BCMA-positive tumors has yet to produce remarkable progress is the paucity of targetable antigens. NKp44 is only expressed by activated natural killer cells and detects a variety of transformed cells, while it reportedly does not react with normal tissues. The aim of this study is to develop CAR-T cell that can target multiple types of tumor cells. Methods: We created a series of novel CAR constructs in first-generation (1G) and second-generation (2G) CAR format with the extracellular immunoglobulin-like domain of NKp44 (NKp44-CAR). Results: Transduction of the best 1G construct into human primary T cells led to specific cytotoxic effects and cytokine secretion upon encountering multiple types of neoplastic cells including AML, T-ALL and childhood solid tumors. Replacement of the extracellular hinge domain of NKp44 with that of CD8α resulted in diminished CAR function. The 1G NKp44-CAR-T cells exhibited significantly better tumor control in long-term co-culture assays compared with activated NK cells, as well as with NK cells transduced with identical NKp44-CAR. T cells transduced with the best 2G-CAR construct with 4-1BB co-stimulatory domain proliferated at significantly higher levels upon single antigen exposure and showed significantly better tumor control compared with the 1G-CAR and 2G-CAR with CD28 co-stimulatory domain. Conclusions: NKp44-based CAR endows T cells with NK cell-like anti-tumor specificity. The CAR gene created in this study will be useful for the development of novel gene-modified T-cell immunotherapy.

    DOI: 10.1002/cti2.1147

    PubMed

    researchmap

  • Fatal Progressive Meningoencephalitis Diagnosed in Two Members of a Family With X-Linked Agammaglobulinemia. International journal

    Yasushi Kasahara, Masaru Imamura, Chansu Shin, Hiroshi Shimizu, Jirou Utsumi, Ryosuke Hosokai, Haruko Iwabuchi, Takayuki Takachi, Akiyoshi Kakita, Hirokazu Kanegane, Akihiko Saitoh, Chihaya Imai

    Frontiers in pediatrics   8   579 - 579   2020

     More details

    Language:English  

    Chronic enteroviral meningoencephalitis is a well-known complication in patients with X-linked agammaglobulinemia (XLA). However, progressive neurodegenerative disorders or chronic neuroinflammatory diseases with no causative microorganisms have been recognized as rare central nervous system (CNS) complications in XLA. We herein report a family in which two of three members with XLA had developed progressive meningoencephalitis with an unknown etiology. A 15-month-old male infant presented with left-sided ptosis. Initially, the family denied any family history of inherited diseases, but later disclosed a family history of agammaglobulinemia previously diagnosed in two family members. In the early 1980s, one of the elder brothers of the index patient's mother who had been treated with intramuscular immunoglobulin [or later intravenous immunoglobulin (IVIG)] for agammaglobulinemia deceased at 10 years of age after showing progressive neurological deterioration during the last several years of his life. The index patient was diagnosed with XLA caused by Bruton tyrosine kinase deficiency (654delG; Val219Leufs*9), and chronic meningoencephalitis with an unknown infectious etiology. Magnetic resonance imaging of the brain demonstrated inflammatory changes in the basal ganglia, hypothalamus, midbrain, and pons, with multiple nodular lesions with ring enhancement, which showed impressive amelioration after the initiation of IVIG replacement therapy. Pleocytosis, which was characterized by an increase in CD4-positive and CD8-positive T cells expressing an activation marker and an elevation in inflammatory cytokines in the cerebrospinal fluid, was identified. No microorganism was identified as a cause of CNS complications. He thereafter developed brain infarction at 19 months of age and fatal status epilepticus at 5 years of age, despite regular IVIG with high trough levels and regular intraventricular immunoglobulin administration. The etiology of this rare CNS complication in XLA is currently unknown. Previous studies have suggested a possible association of IVIG, which was clearly denied in our index case because of the demonstration of his neurological disorder at presentation. In the future, extensive and unbiased molecular methods to detect causative microorganisms, as well as to investigate the possible role of autoimmunity are needed to clarify the etiology of CNS complications.

    DOI: 10.3389/fped.2020.00579

    PubMed

    researchmap

  • BRAFV600E-Positive Precursors as Molecular Markers of Bone Marrow Involvement in Pediatric Langerhans Cell Histiocytosis Reviewed

    Kudo Ko, Kanezaki Rika, Masaru Imamura, Imai Chihaya, Irie Masahiro, Sasahara Yoji, Ando Kumiko, Kakuda Harumi, Doi Takehiko, Kawaguchi Hiroshi, Kudo Kazuko, Kanegane Hirokazu, Kobayashi Akie, Sato Tomohiko, Kamio Takuya, Sasaki Shinya, Terui Kiminori, Toki Tsutomu, Ito Etsuro

    PEDIATRIC BLOOD & CANCER   66   S47   2019.12

  • 小児脳腫瘍のトランスレーショナルリサーチと基礎研究 膠芽腫に対する新たなCAR-T療法の基礎的検討(NKp44-based CAR)

    笠原 靖史, 申 将守, 久保 暢大, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    小児の脳神経   44 ( 2 )   142 - 142   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本小児神経外科学会  

    researchmap

  • 生命と成長を見据えた小児脳腫瘍の集学的治療:胎児性腫瘍と胚細胞性腫瘍 初発髄芽腫に対する術後2週間以内の全脳脊髄照射及びSJMB-96式自家末梢血幹細胞救援併用反復大量化学療法 単一施設での治療経験

    今村 勝, 石井 孝規, 久保 暢大, 笠原 靖史, 岩渕 晴子, 棗田 学, 大石 誠, 今井 千速, 吉村 淳一, 青山 英史, 藤井 幸彦

    小児の脳神経   44 ( 2 )   125 - 125   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本小児神経外科学会  

    researchmap

  • 繰り返す腸重積で発見されフローサイトメトリーでlight chain restrictionを認めた虫垂リンパ過形成の1例

    小貫 孝則, 高地 貴行, 久保 暢大, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    小児科臨床   72 ( 2 )   170 - 174   2019.2

     More details

    Language:Japanese   Publisher:(株)日本小児医事出版社  

    繰り返す腸重積を契機に発見され、フローサイトメトリーでλ鎖優位のlight chain restriction(LCR)を認めた虫垂リンパ過形成の6歳女児例を経験した。腹部造影CTでは最大径2.5cmの全周性虫垂腫大を認め、迅速病理診断およびスタンプ標本からも成熟B細胞リンパ腫で矛盾のない所見を得たが、免疫グロブリン遺伝子やc-myc遺伝子の再構成は認めず、最終的に永久病理標本により虫垂リンパ過形成の診断となった。追加の治療介入は行わず経過観察の方針としたが、約12ヵ月を経過し再発は認めていない。文献上、LCRを認める虫垂リンパ過形成は極めて稀で、4〜6歳の4例が報告されているのみである(すべてλ鎖優位のLCR)。本例の経験から、反復性腸重積の稀な原因として虫垂リンパ過形成があること、そして、反応性の病態ながらもLCRを示す場合があることを念頭に置く必要があることが示された。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J00643&link_issn=&doc_id=20190124480010&doc_link_id=%2Fag1snrsd%2F2019%2F007202%2F010%2F0170-0174%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fag1snrsd%2F2019%2F007202%2F010%2F0170-0174%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 結核疹を伴う播種性BCG感染症を契機に診断されたIFN-γR1部分欠損症

    原田 瑞生, 久保 暢大, 高地 貴行, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 岡田 賢, 今井 千速

    日本小児血液・がん学会雑誌   55 ( 4 )   310 - 310   2018.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • PD-1リガンドを標的とした新規キメラ抗原受容体T細胞の作製(Development of novel chimeric antigen receptor targeting PD-1 ligands in cancer cells)

    申 将守, 久保 暢大, 笠原 靖史, 高地 貴行, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    臨床血液   59 ( 9 )   1587 - 1587   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 多発結節性腎病変を呈した前駆B細胞性急性リンパ性白血病の症例

    中林 大器, 高地 貴行, 久保 暢大, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    小児科臨床   71 ( 8 )   1409 - 1414   2018.8

     More details

    Language:Japanese   Publisher:(株)日本小児医事出版社  

    急性リンパ性白血病(ALL)は腎腫大を含め様々な臓器浸潤を来すが、腎臓に結節性病変を呈することは少ない。症例は1歳4ヵ月の男児。発熱が持続し、血液検査でLDHの異常高値を指摘され、造影CTで両側腎腫大と多発結節性病変を認めた。末梢血中に芽球の出現があり、骨髄穿刺で前駆B細胞性急性リンパ性白血病と診断した。寛解導入療法後に両側腎腫大および腎多発結節性病変は消失し完全寛解に至った。腎の多発結節性病変の鑑別として造血器腫瘍も考慮すべきである。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J00643&link_issn=&doc_id=20180724220012&doc_link_id=%2Fag1snrsd%2F2018%2F007108%2F013%2F1409-1414%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fag1snrsd%2F2018%2F007108%2F013%2F1409-1414%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Detection of Somatic Mutations by PCR-based Next-Generation Sequencing from Fixed Clinical Specimens in Childhood LCH Reviewed

    Ko Kudo, Rika Kanezaki, Akie Kobayashi, Tomohiko Sato, Takuya Kamio, Shinya Sasaki, Kiminori Terui, Atsushi Sato, Masahiro Irie, Yoji Sasahara, Masaru Imamura, Chihaya Imai, Tsutomu Toki, Etsuro Ito

    PEDIATRIC BLOOD & CANCER   64   S14 - S14   2017.11

     More details

    Language:English   Publisher:WILEY  

    Web of Science

    researchmap

  • Detection of Somatic Mutations by PCR-Based Next-Generation Sequencing from Fixed Clinical Specimens in Childhood LCH Reviewed

    Ko Kudo, Rika Kanezaki, Akie Kobayashi, Tomohiko Sato, Takuya Kamio, Shinya Sasaki, Kiminori Terui, Atsushi Sato, Masahiro Irie, Yoji Sasahara, Masaru Imamura, Chihaya Imai, Tsutomu Toki, Etsuro Ito

    PEDIATRIC BLOOD & CANCER   64   S19 - S19   2017.11

     More details

    Language:English   Publisher:WILEY  

    Web of Science

    researchmap

  • 自家末梢血幹細胞移植後のHBV再活性化に対するエンテカビルの使用経験

    久保 暢大, 高地 貴行, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   54 ( 4 )   374 - 374   2017.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • 繰り返す腸重積で発見されλ鎖陽性B細胞のモノクローナル増殖を呈した虫垂atypical lymphoid hyperplasiaの一例

    小貫 孝則, 高地 貴行, 久保 暢大, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   54 ( 4 )   322 - 322   2017.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • EBウイルス関連血球貪食症候群に対する免疫化学療法に合併したClostridium difficile結腸炎の1例

    坂井 知倫, 岩渕 晴子, 久保 暢大, 高地 貴行, 今村 勝, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   54 ( 4 )   375 - 375   2017.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child.

    Haruko Iwabuchi, Hiroyuki Kawashima, Hajime Umezu, Takayuki Takachi, Masaru Imamura, Akihiko Saitoh, Akira Ogose, Chihaya Imai

    International journal of hematology   106 ( 2 )   299 - 303   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Histiocytic sarcoma, a rare hematopoietic neoplasm with evidence of histiocytic differentiation, is often refractory to conventional chemotherapy and radiotherapy, and its prognosis is generally dismal. The optimal management of this malignancy has not been established. We report a case of 8-year-old girl with histiocytic sarcoma involving the left femur. The tumor rapidly responded to a combination of cladribine and high-dose cytosine arabinoside, an aggressive salvage regimen for refractory Langerhans cell histiocytosis, and became impalpable during the first cycle. The patient has remained in complete remission more than 7 years from diagnosis.

    DOI: 10.1007/s12185-017-2202-8

    PubMed

    researchmap

  • Anaplastic large T-cell lymphoma、ALK-positive 胸壁腫瘍治療後に発生したdesmoplasiaを伴う頭蓋内腫瘍

    野澤 孝徳, 伊藤 絢子, 吉村 淳一, 今村 勝, 今井 千速, 岡本 浩一郎, 高橋 均, 梅津 哉, 藤井 幸彦, 柿田 明美

    Brain Tumor Pathology   34 ( Suppl. )   137 - 137   2017.5

     More details

    Language:Japanese   Publisher:日本脳腫瘍病理学会  

    researchmap

  • Anaplastic large T-cell lymphoma、ALK-positiveの1例 縦隔腫瘍に対する化学療法後に発生したdesmoplasiaを伴う頭蓋内腫瘍

    野澤 孝徳, 伊藤 絢子, 清家 尚彦, 齋藤 太希, 渡邉 潤, 塚本 佳広, 吉村 淳一, 今村 勝, 今井 千速, 岡本 浩一郎, 高橋 均, 梅津 哉, 藤井 幸彦, 柿田 明美

    新潟医学会雑誌   131 ( 5 )   311 - 312   2017.5

  • Long term survival of a patient with Perlman syndrome due to novel compound heterozygous missense mutations in RNB domain of DIS3L2. International journal

    Noriko Soma, Ken Higashimoto, Masaru Imamura, Akihiko Saitoh, Hidenobu Soejima, Keisuke Nagasaki

    American journal of medical genetics. Part A   173 ( 4 )   1077 - 1081   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Perlman syndrome is a rare overgrowth syndrome characterized by polyhydramnios, macrosomia, distinctive facial appearance, renal dysplasia, and a predisposition to Wilms' tumor. The syndrome is often associated with a high neonatal mortality rate and there are few reports of long-term survivors. We studied a 6-year-old Japanese female patient, who was diagnosed with Perlman syndrome, with novel compound heterozygous mutations in DIS3L2 (c.[367-2A > G];[1328T > A]), who has survived long term. Most reported DIS3L2 mutations have been the homozygous deletion of exon 6 or exon 9, and these mutations would certainly have caused the loss of both RNA binding and degradation activity. We have identified new compound heterozygous mutations in the DIS3L2 of this long-term survivor of Perlman syndrome. The reason our patient has survived long-term would be a missense mutation (c.1328 T > A, p.Met443Lys) having retained RNA binding in both the cold-shock domains and the S1 domain, and through partial RNA degradation. If partial exonuclease functions remain in at least one allele, long-term survival may be possible. Further studies of Perlman syndrome patients with proven DIS3L2 mutations are needed to clarify genotype-phenotype correlation.

    DOI: 10.1002/ajmg.a.38111

    PubMed

    researchmap

  • 母子感染予防実施後に神経芽腫に対する化学療法を契機としたB型肝炎再活性化の一例

    古寺 一樹, 今村 勝, 久保 暢大, 高地 貴行, 岩渕 晴子, 今井 千速, 齋藤 昭彦

    日本小児科学会雑誌   121 ( 2 )   237 - 237   2017.2

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • ヒトprimary NK細胞へのインターロイキン21遺伝子の導入は抗白血病作用を増強する(Genetic engineering of primary natural killer cells with human Interleukin-21 enhances their anti-leukemic capacity)

    笠原 靖史, 申 将守, 高地 貴行, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   53 ( 4 )   279 - 279   2016.11

     More details

    Language:English   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • 腎芽腫を契機にPerlman症候群と診断された多発奇形を有する6歳女児例

    久保 暢大, 高地 貴行, 岩渕 晴子, 今村 勝, 今井 千速

    日本小児血液・がん学会雑誌   53 ( 4 )   327 - 327   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • 治療関連急性リンパ性白血病の1例

    今村 勝, 久保 暢大, 申 将守, 高地 貴行, 岩渕 晴子, 今井 千速

    臨床血液   57 ( 11 )   2420 - 2420   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 初期治療18年後に眼窩外多発転移再発した両側性網膜芽細胞腫の治療経験(Extraocular multiple metastatic recurrence 18 years after the initial treatment of bilateral retinoblastoma: a case report and literature review)

    高地 貴行, 申 将守, 岩渕 晴子, 今村 勝, 梅津 哉, 川島 寛之, 生越 章, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   53 ( 4 )   364 - 364   2016.11

     More details

    Language:English   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • 髄芽腫術後2週間以内の全脳脊髄照射及びSJM-96式自家末梢血幹細胞救援併用反復大量化学療法の実現可能性(Feasibility of SJMB-96 based repetitive high-dose chemotherapy with PBSC rescue and CSI within two weeks after surgery for medulloblastoma)

    今村 勝, 久保 暢大, 申 将守, 笠原 靖史, 細貝 亮介, 高地 貴行, 吉田 咲子, 岩渕 晴子, 齋藤 昭彦, 青山 英史, 吉村 淳一, 今井 千速

    日本小児血液・がん学会雑誌   53 ( 4 )   360 - 360   2016.11

     More details

    Language:English   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • 自然軽快したEBウイルス関連血球貪食性リンパ組織球症の1例

    皆川 雄介, 申 将守, 高地 貴行, 岩渕 晴子, 今村 勝, 今井 千速, 齋藤 昭彦

    日本小児科学会雑誌   120 ( 5 )   917 - 918   2016.5

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • 小児・思春期再生不良性貧血にウサギATGを使用した免疫抑制治療後のEBV/CMV再活性化 後方視的解析(EBV/CMV reactivation following immunosuppressive therapy with rabbit ATG for children and adolescents with aplastic anemia: A retrospective chart review)

    久保 暢大, 細貝 亮介, 渡辺 彰浩, 小川 淳, 申 将守, 高地 貴行, 笠原 靖史, 吉田 咲子, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   52 ( 4 )   313 - 313   2015.10

     More details

    Language:English   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • 全脳脊髄照射を要する小児脳腫瘍における術後2週間以内のG-CSF単独自家末梢血幹細胞採取

    細貝 亮介, 高地 貴行, 吉田 咲子, 岩渕 晴子, 今村 勝, 申 将守, 笠原 靖史, 齋藤 昭彦, 佐野 正和, 西山 健一, 阿部 英輔, 青山 英史, 吉村 淳一, 今井 千速

    日本小児血液・がん学会雑誌   52 ( 2 )   133 - 138   2015.8

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    悪性脳腫瘍に対する全脳脊髄照射(CSI)では頭蓋骨及び全脊椎の骨髄組織が障害されるため、CSI後の強力な化学療法では骨髄抑制が著しく遷延し、結果的に治療全体の強度が低下することが大きな問題である。そこで我々は、CSI及び強力な化学療法を要する悪性脳腫瘍に対しG-CSF単独の末梢血幹細胞(PBSC)採取を試み、化学療法に自家末梢血幹細胞移植(aPBSCT)を併用することとした。早期にCSIを開始するため、術後2週以内の採取完了を目指した。初発未治療例6例では中央値12.6×10^6/kg(3.9-21.6×10^6/kg)のCD34陽性細胞採取が可能だったが、うち2例では複数回のaPBSCTに十分な細胞数に達しなかった。再発例の2例では少なくとも1回の移植に必要な量は採取できた。これら4例ではaPBSCT併用化学療法1コース終了後に再度PBSC採取を行い十分量が確保できた(13.7-42.1×10^6/kg)。術後2週以内のPBSC採取では白血球数が増加しやすい傾向にあったが、重篤な有害事象はみられなかった。全例で予定した複数回aPBSCTを実施でき、骨髄抑制の遷延をきたすことなく規定の間隔で化学療法を完遂できた。術後2週以内のG-CSF単独PBSC採取は安全に実施できたものの少数例の経験であり、術後早期にCSIを要する悪性脳腫瘍の集学的治療における有効性に関しては更なる検討を要する。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J06030&link_issn=&doc_id=20160106240003&doc_link_id=%2Fex9syoga%2F2015%2F005202%2F003%2F0133-0138%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fex9syoga%2F2015%2F005202%2F003%2F0133-0138%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 慢性髄膜脳炎と脳梗塞を合併したX連鎖無ガンマグロブリン血症に対する脳室内免疫グロブリン治療の成功例

    笠原 靖史, 申 将守, 高地 貴行, 岩渕 晴子, 今村 勝, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   51 ( 4 )   291 - 291   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • インターフェロン、サリドマイド、プロプラノロールが無効で治療に苦慮しているびまん性肺リンパ管腫症の1例

    今村 勝, 岩渕 晴子, 吉田 咲子, 高地 貴行, 細貝 亮介, 笠原 靖史, 申 将守, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会雑誌   51 ( 4 )   326 - 326   2014.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    researchmap

  • Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. International journal

    Masaru Imamura, David Shook, Takahiro Kamiya, Noriko Shimasaki, Sally M H Chai, Elaine Coustan-Smith, Chihaya Imai, Dario Campana

    Blood   124 ( 7 )   1081 - 8   2014.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Natural killer (NK) cell survival and, hence, cytotoxicity requires cytokine support. We determined whether expression of interleukin-15 (IL-15) in a nonsecretory, membrane-bound form could sustain NK cell growth. We linked the human IL15 gene to that encoding CD8α transmembrane domain (mbIL15). After retroviral transduction, human NK cells expressed mbIL15 on the cell surface; IL-15 secretion was negligible. Survival of mbIL15-NK cells without interleukin-2 (IL-2) after 7-day culture was vastly superior to that of mock-transduced NK cells (P < .001, n = 15) and of NK cells expressing nonmembrane-bound IL-15 (P = .025, n = 9); viable mbIL15-NK cells were detectable for up to 2 months. In immunodeficient mice, mbIL15-NK cells expanded without IL-2 and were detectable in all tissues examined (except brain) in much higher numbers than mock-transduced NK cells (P < .001). Expansion further increased with IL-2. The primary mechanism of mbIL15 stimulation was autocrine; it activated IL-15 signaling and antiapoptotic signaling. NK cells expressing mbIL15 had higher cytotoxicity against leukemia, lymphoma, and solid tumor cells in vitro and against leukemia and sarcoma cells in xenograft models. Thus, mbIL15 confers independent growth to NK cells and enhances their antitumor capacity. Infusion of mbIL15-NK cells would allow NK cell therapy without the potential adverse effects of cytokine administration.

    DOI: 10.1182/blood-2014-02-556837

    PubMed

    researchmap

  • 新潟県における消化管原発リンパ腫の実態

    高橋 みのり, 小川 淳, 今井 千速, 渡辺 輝浩, 申 将守, 笠原 靖史, 細貝 亮介, 高地 貴行, 吉田 咲子, 岩渕 晴子, 今村 勝, 浅見 恵子, 新潟小児血液研究会

    日本小児科学会雑誌   118 ( 7 )   1139 - 1139   2014.7

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • 超大量メソトレキセート療法の毒性発現機序 高サイトカイン血症の介在の可能性

    笠原 靖史, 吉田 咲子, 高地 貴行, 細貝 亮介, 岩渕 晴子, 今村 勝, 川島 寛之, 生越 章, 齋藤 昭彦, 今井 千速

    日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号   55回・11回・18回   309 - 309   2013.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会  

    researchmap

  • Alveolar rhabdomyosarcoma after treatment of osteosarcoma. International journal

    Yasushi Kasahara, Haruko Iwabuchi, Takayuki Takachi, Ryosuke Hosokai, Sakiko Yoshida, Masaru Imamura, Akihiro Watanabe, Hajime Umezu, Tetsuo Hotta, Akira Ogose, Chihaya Imai

    Pediatrics international : official journal of the Japan Pediatric Society   55 ( 4 )   527 - 30   2013.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Secondary rhabdomyosarcoma (RMS) after treatment of osteosarcoma (OS) is rare. Reported here is the case of a metachronous RMS in the nasal cavity, developing 12 years after successful treatment of non-metastatic OS. The patient was diagnosed as having OS of the femur at 2 years of age. Chemotherapy for OS included doxorubicin (cumulative dose, 488 mg/m(2) ). No radiotherapy was given. There was no family history suggestive of cancer predisposition syndrome. At 14 years of age, alveolar RMS was diagnosed on histopathology. PAX3-FKHR fusion transcripts were detected on reverse transcription-polymerase chain reaction. Germline TP53 mutation was not seen on standard DNA sequencing. The occurrence of secondary sarcomas, in the Children's Cancer Survivor study conducted in North America, has been associated with high cumulative doses of anthracyclines, which may also have played a role in the development of RMS in the present case. In the future, novel molecular technologies might uncover genetic cancer predisposition in patients with metachronous cancers.

    DOI: 10.1111/ped.12070

    PubMed

    researchmap

  • Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. International journal

    Akihiro Watanabe, Shin Chansu, Atsushi Ogawa, Keiko Asami, Masaru Imamura

    Pediatrics international : official journal of the Japan Pediatric Society   55 ( 3 )   e56-8   2013.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Philadelphia chromosome-positive acute lymphoblastic leukemia has a poor prognosis, even in pediatric patients. Although imatinib-containing chemotherapy can reportedly improve early event-free survival, allogeneic hematopoietic stem cell transplantation is still considered to be the main curative treatment option. Dasatinib, a novel abl tyrosine kinase inhibitor, is being used for the treatment of relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia and is reported to have excellent efficacy. We used dasatinib after bone marrow transplantation prior to the anticipated relapse for the purpose of prophylaxis against relapse. After discontinuation of dasatinib administration, molecular remission has lasted for 7 months. Although preventive use of dasatinib is as yet uncommon, we consider that dasatinib may eradicate the minimal residual disease and prevent recurrence, and it is feasible to administer and appears to be safe. Further studies are needed to confirm our experience in this case.

    DOI: 10.1111/ped.12019

    PubMed

    researchmap

  • 血管腫・リンパ管腫(症)に対するプロプラノロール治療の経験

    笠原 靖史, 細貝 亮介, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 齋藤 昭彦

    日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号   54回・10回・17回   418 - 418   2012.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会  

    researchmap

  • 家系に複数の脾臓摘出者を認め遺伝性球状赤血球症と考えられていたHb Koeln症の一例

    笠原 靖史, 細貝 亮介, 高地 貴行, 吉田 咲子, 今村 勝, 今井 千速

    日本小児血液・がん学会雑誌   49 ( 1-2 )   138 - 141   2012.5

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    先天性溶血性貧血の異常部位には赤血球膜、赤血球酵素、ヘモグロビンが知られている。遺伝性球状赤血球症(HS)は赤血球膜の異常に起因し、日本で最も高頻度の先天性溶血性貧血である。溶血性貧血を呈し、HSに矛盾しない背景を持つ場合では、他の稀な溶血性貧血が見逃される可能性も考えられる。Hb Koeln症はヘモグロビン異常症の一型で、稀な疾患である。今回、我々は複数の脾臓摘出者を認め、HSと考えられていた12歳男児のHb Koeln症を経験した。平均赤血球ヘモグロビン濃度(MCHC)は28.7%と低値、平時のSpO2は90%程と低値(高濃度酸素投与で92%)、HbA1cは2.0%と異常低値であった。これらの一般検査所見がHSとは矛盾したため、ヘモグロビン異常症を疑い精査を進めた。先天性溶血性貧血のような稀な疾患でも、日常的な検査の吟味が診断に重要と考えられた。(著者抄録)

    researchmap

  • ICE療法が著効した脈絡叢癌の2例

    鈴木 亮, 吉田 咲子, 今村 勝, 細貝 亮介, 高地 貴行, 今井 千速, 内山 聖, 吉村 淳一, 西山 健一

    日本小児科学会雑誌   116 ( 5 )   889 - 889   2012.5

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • Langerhans cell histiocytosisの1例

    藤川 大基, 三井田 博, 佐藤 信之, 細貝 亮介, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖

    日本皮膚科学会雑誌   122 ( 2 )   400 - 400   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    researchmap

  • Lymphoblastic lymphoma with mature b-cell immunophenotype and MLL-AF9 in a child. International journal

    Takayuki Takachi, Haruko Iwabuchi, Masaru Imamura, Chihaya Imai

    Pediatric blood & cancer   57 ( 7 )   1251 - 2   2011.12

     More details

    Language:English  

    DOI: 10.1002/pbc.23228

    PubMed

    researchmap

  • 濃厚な摘脾の家族歴を有し遺伝性球状赤血球症と診断されていたHb Koeln症の一症例

    笠原 靖史, 細貝 亮介, 高地 貴行, 吉田 咲子, 今村 勝, 今井 千速

    小児がん   48 ( プログラム・総会号 )   257 - 257   2011.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • 全脳全脊髄照射を要する小児脳腫瘍における術後超早期のG-CSF単独自家末梢血幹細胞採取の実施可能性

    細貝 亮介, 笠原 靖史, 高地 貴行, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 吉村 淳一, 西山 健一

    小児がん   48 ( プログラム・総会号 )   223 - 223   2011.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • Disseminated BCG infection mimicking metastatic nasopharyngeal carcinoma in an immunodeficient child with a novel hypomorphic NEMO mutation. International journal

    Masaru Imamura, Tomoki Kawai, Satoshi Okada, Kazushi Izawa, Takayuki Takachi, Haruko Iwabuchi, Sakiko Yoshida, Ryosuke Hosokai, Hirokazu Kanegane, Tatsuo Yamamoto, Hajime Umezu, Ryuta Nishikomori, Toshio Heike, Makoto Uchiyama, Chihaya Imai

    Journal of clinical immunology   31 ( 5 )   802 - 10   2011.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Nuclear factor-κB essential modulator (NEMO) deficiency is a developmental and immunological disorder. The genetic and phenotypic correlation has been described. METHODS: We report a unique clinical presentation and the identification of a novel missense mutation in the NEMO gene in a 3-year-old boy with bacillus Calmette-Guerin (BCG) infection. RESULTS: The patient presented with fever, cervical lymphadenopathy, and abnormal anti-Epstein-Barr virus (EBV) antibody titers, suggestive of EBV-related diseases including chronic active EBV infection, X-linked lymphoproliferative syndrome, or nasopharyngeal carcinoma. Although the biopsy specimen from a nasopharyngeal lesion was initially diagnosed as squamous cell carcinoma, this was changed to disseminated BCG infection involving the nasopharynx, multiple systemic lymph nodes, and brain. A novel mutation (designated D311E) in the NEMO gene, located in the NEMO ubiquitin-binding (NUB) domain, was identified as the underlying cause of the immunodeficiency. Impaired immune responses which are characteristic of patients with NEMO deficiency were demonstrated. The patient underwent successful unrelated bone marrow transplantation at 4.9 years of age. CONCLUSION: This study suggests the importance of the NUB domain in host defense against mycobacteria. The unique presenting features in our patient indicate that a hypomorphic NEMO mutation can be associated with atypical pathological findings of the epithelial tissues in patients with BCG infection.

    DOI: 10.1007/s10875-011-9568-9

    PubMed

    researchmap

  • 急性リンパ性白血病治療中に発症し、アムホテリシンBリポソーム製剤が奏効した接合菌症の疑われる脳膿瘍の1例

    細貝 亮介, 高地 貴行, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖

    日本小児血液学会雑誌   25 ( 2 )   97 - 101   2011.4

     More details

    Language:Japanese   Publisher:日本小児血液学会  

    3歳男児。B前駆細胞型小児急性リンパ性白血病(ALL)と診断し、超高危険群として寛解導入療法を開始した。治療開始42週目に2回目の再寛解導入療法に続く強化療法を開始した。一時解熱したが再度発熱し、発熱から10日後に全身強直性痙攣が出現した。頭部CTで右頭頂葉に輪状造影を伴う病変を認め、脳膿瘍が疑われた。接合菌症の可能性を考慮してliposomal amphotericin B(L-AMB)を開始したところ翌日には解熱し、発症2週後のDiffusion MRIでは右頭頂葉に膿瘍腔を示唆する高信号域を認めていたが、発症2ヵ月後には消失していた。しかし、CRPは0.3〜1.0mg/dl程度で著減していたため、L-AMB継続下にmercaptopurine(6MP)、methotrexate(MTX)内服による維持療法を開始した。発症4ヵ月後もDiffusion MRIの所見は変化を認めなかったが、血清クレアチニンは0.2mg/dlから0.5mg/dlへ上昇した。そのためL-AMBを5mg/kg/dayの隔日投与へ、さらに2週間後から週2回投与へ減量したが、CRPは増加傾向とはならなかった。Diffusion MRI所見の増悪もなく、週2回投与を2週間継続後にL-AMBを中止した。その後CRPは陰性化し、投与終了後約1年、脳膿瘍の再発は認めず、維持療法継続中である。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J02258&link_issn=&doc_id=20110511060006&doc_link_id=%2Fex9syoke%2F2011%2F002502%2F006%2F0097-0101%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fex9syoke%2F2011%2F002502%2F006%2F0097-0101%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 小児髄芽腫に対する新たな集学的治療の取り組み

    細貝 亮介, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖, 吉村 淳一, 西山 健一

    日本小児科学会雑誌   115 ( 4 )   832 - 832   2011.4

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • Reactive tonsillar enlargement with strong 18F-FDG uptake after chemotherapy for tonsillar diffuse large B-cell lymphoma. International journal

    Ryosuke Hosokai, Chihaya Imai, Takayuki Takachi, Sakiko Yoshida, Haruko Iwabuchi, Masaru Imamura, Makoto Uchiyama

    Journal of pediatric hematology/oncology   33 ( 2 )   e87-8   2011.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We describe a 14-year-old boy who exhibited left palatine tonsillar enlargement after 6 cycles of aggressive chemotherapy for diffuse large B-cell lymphoma of the right palatine tonsil. The cervical computed tomography scan at 4 months after completion of chemotherapy revealed enlargement of the left palatine tonsil in addition to the thymus without any clinical symptoms. The F-fluorodeoxyglucose positron emission tomography indicated focal areas of strong F-fluorodeoxyglucose uptake in the left palatine tonsil. Histologic examination confirmed tonsillar hyperplasia with no evidence of recurrence. Reactive tonsillar hyperplasia after chemotherapy is rarely reported.

    DOI: 10.1097/MPH.0b013e3181f69205

    PubMed

    researchmap

  • 発作性寒冷血色素性尿症にHHV-6関連急性脳症を合併した一例

    橋本 聖子, 細貝 亮介, 高地 貴行, 吉田 咲子, 岩渕 晴子, 今村 勝, 大橋 伯, 今井 千速, 内山 聖

    日本小児科学会雑誌   115 ( 2 )   498 - 498   2011.2

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • イマチニブ併用化学療法及び臍帯血移植により完全寛解を維持しているdouble Ph陽性ALLの一例

    吉田 咲子, 細貝 亮介, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖

    小児がん   47 ( プログラム・総会号 )   434 - 434   2010.12

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • 小児がん化学療法中の口内炎予防 GFO(医療用食品)服用を導入した2事例の検討

    馬場 光紀, 伊藤 望, 三富 智子, 住吉 智子, 細貝 亮介, 吉田 咲子, 岩淵 晴子, 今村 勝, 今井 千速

    小児がん   47 ( プログラム・総会号 )   360 - 360   2010.12

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • 複雑染色体異常を有し自然軽快傾向を認めている新生児急性骨髄性白血病の1例

    今村 勝, 細貝 亮介, 吉田 咲子, 岩渕 晴子, 今井 千速, 内山 聖

    小児がん   47 ( プログラム・総会号 )   416 - 416   2010.12

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • 扁桃リンパ腫に対する化学療法終了後に生じたPETシンチ強陽性の対側扁桃過形成

    藤井 小弥太, 黒沢 大樹, 細貝 亮介, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖

    日本小児科学会雑誌   114 ( 5 )   899 - 899   2010.5

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • T細胞性白血病細胞株に対するヒストン脱アセチル化酵素阻害剤の抗腫瘍効果とNK細胞療法との併用の検討

    高地 貴行, 根本 妙, 岩渕 晴子, 吉田 咲子, 今村 勝, 今井 千速, 内山 聖

    日本小児科学会雑誌   114 ( 5 )   898 - 898   2010.5

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • A 2-year-old boy with a stage III yolk sac tumor occurring in an intra-abdominal retained testis. International journal

    Yutaka Hirayama, Masayuki Kubota, Masaru Imamura, Chihaya Imai, Naoki Okuyama, Mami Tsukada, Kumiko Kobayashi, Kanako Sato, Takayuki Takachi, Haruko Iwavuchi, Makoto Uchiyama

    Journal of pediatric surgery   44 ( 12 )   2395 - 8   2009.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A major complication of retained testes is an occurrence of malignancy later in life. We, herein, report the case of a 2-year-old boy who presented with a huge yolk sac tumor with retroperitoneal lymph nodes metastasis that originated in a left intra-abdominal undescended testis. Computed tomography and magnetic resonance imaging showed a huge round tumor connecting to the left retroperitoneal lymph nodes with metastasis extending from the left pelvic region to the left renal hilum. The serum alpha-fetoprotein level was 36,528 ng/mL. The right abdominal tumor appeared to be a giant testis that had strangulated at the neck of the cord. The tumor had ruptured at the side of the left pelvic lymph node metastasis, and a yolk sac tumor was diagnosed from a histologic analysis of the resected specimens. Postoperative PEB chemotherapy was effective, and a complete surgical resection of the tumor was performed 3 months after the initial laparotomy. The pathologic findings showed fibrous tissue without any tumor cells. The patient has been doing well for 18 months after the radical operation. This case might be a coincidental association of a yolk sac tumor occurring in an undescended testis, which thus caused a delay in making an accurate diagnosis.

    DOI: 10.1016/j.jpedsurg.2009.08.024

    PubMed

    researchmap

  • 腸重積を契機に発見されたBurkittリンパ腫の2例

    田中 雅人, 細貝 亮介, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖

    日本小児科学会雑誌   113 ( 12 )   1886 - 1886   2009.12

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • 急性リンパ性白血病治療中に発症し、アムホテリシンBリポソーム製剤が奏功した接合菌症の疑われる脳膿瘍の1例

    細貝 亮介, 吉田 咲子, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖

    小児がん   46 ( プログラム・総会号 )   451 - 451   2009.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • 新潟県における乳児期神経芽腫マススクリーニング休止後の症例動向と問題点について

    平山 裕, 窪田 正幸, 浅見 恵子, 今井 千速, 奥山 直樹, 塚田 真実, 今村 勝, 吉田 咲子, 細貝 亮介, 高地 貴行, 渡辺 輝浩, 小川 淳

    小児がん   46 ( プログラム・総会号 )   309 - 309   2009.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • 化学療法で食事制限がある小児と家族への食事ガイドの作成 段階別の食事ガイドの試み

    塩谷 祐子, 伊藤 望, 住吉 智子, 今井 千速, 今村 勝, 吉田 咲子, 岩淵 晴子, 細貝 亮介, 高地 貴行

    小児がん   46 ( プログラム・総会号 )   319 - 319   2009.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • 化学療法中の小児と家族の食事に関する認識と行動 小児がん患者のQOL向上のための食事ガイド作成に向けて

    伊藤 望, 塩谷 祐子, 住吉 智子, 今井 千速, 今村 勝, 吉田 咲子, 岩淵 晴子, 細貝 亮介, 高地 貴行

    小児がん   46 ( プログラム・総会号 )   320 - 320   2009.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • A novel homozygous 8-base pair deletion mutation in the glycoprotein Ibalpha gene in a patient with Bernard-Soulier syndrome. International journal

    Chihaya Imai, Shinji Kunishima, Takayuki Takachi, Haruko Iwabuchi, Tae Nemoto, Masaru Imamura, Makoto Uchiyama

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis   20 ( 6 )   470 - 4   2009.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We present a patient with Bernard-Soulier syndrome harboring a novel mutation. Flow cytometric analysis showed that the glycoprotein (GP) Ib/IX complex was absent from the platelet surface. By immunoblotting, GPIbalpha, GPIbbeta and GPIX were not detected in the platelet lysates. Glycocalicin, the soluble GPIbalpha fragment, was also absent in the plasma. Genetic analysis revealed a novel homozygous 8-base pair deletion in the GPIbalpha gene, 1136_1143delTTCACATG, which was predicted to cause a frame shift and the addition of 13 altered amino acids followed by premature termination. No mutation was found in the coding sequence of the GPIbbeta or GPIX genes. We demonstrated that the novel deletion mutation resulted in complete defectiveness of the GPIbalpha protein and null expression of the entire GPIb/IX complex, and was responsible for the Bernard-Soulier syndrome phenotype in this patient. Although the presence of a truncated GPIbalpha protein has been often documented, complete absence of the protein has been scarcely reported in Bernard-Soulier syndrome patients with a GPIbalpha mutation causing a premature stop codon. An underlying molecular mechanism to explain how the synthesis of a truncated protein is inhibited in selected cases remains to be elucidated.

    DOI: 10.1097/MBC.0b013e32832b27fa

    PubMed

    researchmap

  • 臍帯血移植生着後の患者血液からのドナー由来Natural Killer(NK)細胞の体外増幅

    今井 千速, 高地 貴行, 岩渕 晴子, 小川 淳, 渡辺 輝浩, 浅見 恵子, 細貝 亮介, 今村 勝, 吉田 咲子, 内山 聖

    臨床血液   50 ( 9 )   1116 - 1116   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Expression of liver X receptor alpha and lipid metabolism in granulocyte-macrophage colony-stimulating factor-induced human monocyte-derived macrophage. International journal

    Toshihiro Kazawa, Takashi Kawasaki, Azusa Sakamoto, Masaru Imamura, Riuko Ohashi, Shuying Jiang, Toshiya Tanaka, Hiroko Iwanari, Takao Hamakubo, Juro Sakai, Tatsuhiko Kodama, Makoto Naito

    Pathology international   59 ( 3 )   152 - 60   2009.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Liver X receptor (LXR) is a nuclear receptor that acts as a sterol sensor and metabolic regulator of cholesterol and lipid homeostasis. The foam cell transformation of macrophages (Mvarphi) is considered a critical process in atherosclerotic lesions. The relationship, however, of the foam cell transformation of Mvarphi and LXR is not fully understood. The purpose of the present study was to examine the expression of LXRalpha, retinoid X receptor (RXR)alpha, ATP-binding cassette transporter (ABCA1), and macrophage scavenger receptor A (MSR-A), and lipid accumulation in human monocyte-derived Mvarphi. The expression of LXRalpha, ABCA1, MSR-A in 7 day cultured granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced Mvarphi (GM-Mvarphi) was significantly higher than that in 7 day cultured M-CSF-induced Mvarphi (M-Mvarphi). The expression levels of LXRalpha, ABCA1 and MSR-A protein decreased from 48 h to 5 days after the addition of lipopolysaccharide (LPS) in GM-Mvarphi, but only MSR-A protein decreased at 5 days after the addition of LPS in M-Mvarphi. Intracellular lipid accumulation was clearly observed when GM-Mvarphi was pre-stimulated with LPS for 48 h and incubated with oxidized LDL for an additional 5 days. These findings suggest that the inhibitory activity of LXRalpha, ABCA1 and MSR-A by LPS may be related to the transformation of Mvarphis, especially GM-Mvarphi into foam cells.

    DOI: 10.1111/j.1440-1827.2009.02343.x

    PubMed

    researchmap

  • 骨肉腫治療後二次性に発生したPAX3-FKHR陽性の横紋筋肉腫の一例

    笠原 靖史, 今井 千速, 今村 勝, 高地 貴行

    小児がん   45 ( プログラム・総会号 )   394 - 394   2008.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • ヒストン脱アセチル化酵素阻害剤とヒトNK細胞を併用したT細胞性白血病細胞株に対する抗腫瘍効果

    高地 貴行, 笠原 靖史, 今村 勝, 今井 千速, 内山 聖

    小児がん   45 ( プログラム・総会号 )   362 - 362   2008.11

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • Juvenile myelomonocytic leukemia with less aggressive clinical course and KRAS mutation. International journal

    Masaru Imamura, Chihaya Imai, Takayuki Takachi, Tae Nemoto, Atsushi Tanaka, Makoto Uchiyama

    Pediatric blood & cancer   51 ( 4 )   569 - 569   2008.10

     More details

    Language:English  

    DOI: 10.1002/pbc.21626

    PubMed

    researchmap

  • IL-2遺伝子導入NK細胞の生存促進と抗腫瘍効果の持続的発現

    今井 千速, 高地 貴行, 今村 勝, 岩渕 晴子, 笠原 靖史, 根本 妙, 内山 聖

    臨床血液   49 ( 9 )   1005 - 1005   2008.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 播種性BCG感染症が疑われる一例

    安藤 麻理, 高地 貴之, 今村 勝, 今井 千速, 長谷川 剛, 梅津 哉, 内藤 眞

    日本リンパ網内系学会会誌   48   107 - 107   2008.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions Reviewed

    A. S. Savchenko, M. Imamura, R. Ohashi, S. Jiang, T. Kawasaki, G. Hasegawa, I. Emura, H. Iwanari, M. Sagara, T. Tanaka, T. Hamakubo, T. Kodama, M. Naito

    JOURNAL OF PATHOLOGY   215 ( 1 )   48 - 55   2008.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JOHN WILEY & SONS LTD  

    Pentraxin 3 (PTX3) and C-reactive protein (CRP) are members of the pentraxin superfamily. PTX3 expression is induced in response to inflammatory signals, and is produced at sites of inflammation by several types of cell, primarily monocytes/macrophages, dendritic cells (DCs), endothelial cells, smooth muscle cells (SMCs), and fibroblasts, but is not produced by hepatocytes, which are a major source of CRP. The aim of our study was to investigate the expression pattern of PTX3 in human atherosclerotic lesions using a novel monoclonal antibody against PTX3. We examined coronary arterial thrombi containing an atherosclerotic plaque component removed from patients with acute myocardial infarction and human aortic tissues with various degrees of atherosclerosis sampled from autopsy cases. Immunohistochemical study of paraffin and frozen sections indicated that macrophages, mainly foam cells, expressed PTX3 in advanced atherosclerotic lesions. Interestingly, we also clearly observed PTX3-positive neutrophils infiltrating into atherosclerotic plaques, suggesting that PTX3 derived from neutrophils as well as macrophages plays an important role in atherogenesis. Copyright (C) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

    DOI: 10.1002/path.2314

    Web of Science

    researchmap

  • 自然軽快しているK-rasの変異を認めた若年性骨髄単球性白血病の1例

    今村 勝, 今井 千速, 岩渕 晴子, 高地 貴行, 内山 聖

    小児がん   44 ( プログラム・総会号 )   313 - 313   2007.12

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • MLL遺伝子再構成(MLL-AF9)が検出された、成熟B細胞の形質を呈するリンパ芽球型リンパ腫の一例

    高地 貴行, 岩渕 晴子, 今村 勝, 今井 千速, 内山 聖

    小児がん   44 ( プログラム・総会号 )   291 - 291   2007.12

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • Lipopolysaccharide induced expression of pentraxin 3 in human neutrophils and monocyte-derived macrophages. International journal

    Masaru Imamura, Takashi Kawasaki, Alexander S Savchenko, Riuko Ohashi, Shuying Jiang, Kyoko Miyamoto, Yukio Ito, Hiroko Iwanari, Mina Sagara, Toshiya Tanaka, Takao Hamakubo, Tatsuhiko Kodama, Makoto Uchiyama, Makoto Naito

    Cellular immunology   248 ( 2 )   86 - 94   2007.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Pentraxin 3 (PTX3) is a prototype protein of long pentraxin. PTX3 is produced by various cells, such as monocytes/macrophages (Mphis) in response to lipopolysaccharide (LPS) and proinflammatory signals. We performed immunoblotting, immunohistochemical staining, reverse transcriptase-polymerase chain reaction (RT-PCR), quantitative real-time PCR and enzyme-linked immunosorbent assay (ELISA) of PTX3 in human monocyte-derived Mphis and neutrophils. PTX3 expression was observed in the cytoplasm of both GM-CSF induced monocyte-derived Mphi (GM-Mphi) and M-CSF induced monocyte-derived Mphi (M-Mphi). PTX3 level in both Mphis was up-regulated at 24 h after LPS stimulation. Moreover, we confirmed PTX3 expression in freshly isolated neutrophils, and PTX3 level was distinctly up-regulated at 6 and 24 h after LPS stimulation. These findings suggested that PTX3 expression, not only in Mphis, but also in neutrophils, may reflect the role of PTX3 in inflammation. We believe that PTX3 can contribute as a diagnostic tool to evaluate inflammation at peripheral sites.

    PubMed

    researchmap

  • Duplication of chromosome 4q: renal pathology of two siblings. International journal

    Taketo Otsuka, Hidehiko Fujinaka, Masaru Imamura, Yasuki Tanaka, Hiroshi Hayakawa, Shuichi Tomizawa

    American journal of medical genetics. Part A   134 ( 3 )   330 - 3   2005.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We report on two sibs with partial 4q trisomy: dup (4)(q35.2-q31.22) and their renal biopsy findings. Both of them show renal hypoplasia, although their chromosomal aberration lacks the minimal duplicated region 4q22-q23 and/or 4q25-q31.3, which had been shown to be associated with urogenital abnormalities and thumb malformations in previous reports. From the renal biopsy findings, the two sibs were diagnosed as oligonephronia. We summarize the 13 having published cases of duplication of chromosome 4q, and examine which segments have a close relationship to renal hypoplasia. We suggest that renal hypoplasia may be female-prone, and may have a close relationship with duplication of 4q33-q34.

    PubMed

    researchmap

  • Primary tuberculous osteomyelitis of the mandible. International journal

    Masaru Imamura, Toshio Kakihara, Kohsuke Yamamoto, Chihaya Imai, Atsushi Tanaka, Makoto Uchiyama

    Pediatrics international : official journal of the Japan Pediatric Society   46 ( 6 )   736 - 9   2004.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PubMed

    researchmap

  • Mitochondrial trifunctional protein deficiency in a lethal neonate. International journal

    Hajime Yamazaki, Katsumi Torigoe, Osamu Numata, Hisanori Haniu, Asami Uchiyama, Yohei Ogawa, Utako Kaneko, Masaru Imamura, Satoshi Hasegawa

    Pediatrics international : official journal of the Japan Pediatric Society   46 ( 2 )   178 - 80   2004.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PubMed

    researchmap

▶ display all

MISC

  • BRAFV600E-positive precursors as molecular markers of bone marrow disease in LCH(和訳中)

    工藤 耕, 土岐 力, 金崎 里香, 小林 明恵, 佐藤 知彦, 神尾 卓哉, 佐々木 伸也, 今村 勝, 今井 千速, 安藤 久美子, 角田 治美, 土居 岳彦, 川口 浩史, 入江 正寛, 笹原 洋二, 田村 彰広, 長谷川 大一郎, 板倉 陽介, 渡邉 健一郎, 深野 玲司, 坂本 謙一, 塩田 曜子, 加藤 元博, 工藤 寿子, 金兼 弘和, 伊藤 悦朗, 照井 君典

    日本血液学会学術集会   83回   OS2 - 2   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • NKp44キメラ抗原受容体による新しいがん免疫治療の開発

    笠原 靖史, 久保 暢大, 申 将守, 高地 貴行, 岩渕 晴子, 今村 勝, 今井 千速

    日本小児科学会雑誌   123 ( 6 )   1062 - 1062   2019.6

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    researchmap

  • Adoptive T Cell Immunotherapy Against a Wide Range of Malignancies by Using Chimeric Antigen Receptors with NK cell-like Specificity (NKp44-CAR)

    Yasushi Kasahara, Changsu Shin, Takayuki Takachi, Nobuhiro Kubo, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai

    PEDIATRIC BLOOD & CANCER   64   S22 - S22   2017.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • A Novel NKp44-Based Chimeric Antigen Receptor That Targets Multiple Types of Cancer

    Yasushi Kasahara, Changsu Shin, Sakiko Yoshida, Takayuki Takachi, Nobuhiro Kubo, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Interleukin-21 Gene Transduction in Human Natural Killer Cells Enhances Their Anti-Leukemic Capacity

    Yasushi Kasahara, Changsu Shin, Takayuki Takachi, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 易感染性にある小児がん患児の食支援モバイル型携帯サイトツールの有効性の検討

    住吉 智子, 伊藤 望, 田中 美央, 柿沼 佐代子, 岡崎 章, 今井 千速, 今村 勝

    小児がん   47 ( プログラム・総会号 )   360 - 360   2010.12

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    researchmap

  • Patients&apos; Peripheral Blood as a Possible Source of Donor-Derived NK Cells for Ex Vivo Expansion and Genetic Modification for Post-Transplant Cellular Immunotherapy In Cord Blood Recipients

    Chihaya Imai, Sakiko Yoshida, Takayuki Takachi, Masaru Imamura, Ryosuke Hosokai, Haruko Iwabuchi, Makoto Uchiyama, Keiko Asami, Atsushi Ogawa, Akihiro Watanabe

    BLOOD   116 ( 21 )   868 - 869   2010.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 1 成熟B細胞の形質を呈しMLL遺伝子再構成を認めたリンパ芽球型リンパ腫の1例(I.一般演題,第42回新潟血液同好会)

    高地 貴行, 岩渕 晴子, 今村 勝, 今井 千速

    新潟医学会雑誌   122 ( 7 )   402 - 402   2008.7

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

▶ display all

Research Projects

  • メモリー様分化誘導を基盤とした多種類のがんに有効なCAR-NK細胞製剤の新規開発

    Grant number:22H03036

    2022.4 - 2025.3

    System name:科学研究費助成事業

    Research category:基盤研究(B)

    Awarding organization:日本学術振興会

    今井 千速, 三原 圭一朗, 今村 勝

      More details

    Grant amount:\17030000 ( Direct Cost: \13100000 、 Indirect Cost:\3930000 )

    researchmap

  • メモリー様分化誘導を基盤とした多種類のがんに有効なCAR-NK細胞製剤の新規開発

    Grant number:23K24297

    2022.4 - 2025.3

    System name:科学研究費助成事業

    Research category:基盤研究(B)

    Awarding organization:日本学術振興会

    今井 千速, 三原 圭一朗, 久保 貴紀, 今村 勝

      More details

    Grant amount:\17030000 ( Direct Cost: \13100000 、 Indirect Cost:\3930000 )

    第3者健常成人由来CAR-NK細胞製剤の新規開発を最終目標に、本研究ではメモリー様NK細胞の製造法の新規技術ならびに新規CAR遺伝子の開発を目指して、(1)NK細胞のメモリー様分化の分子基盤と誘導法の解明、製造法および遺伝子改変法の確立、(2)膜型サイトカインの新規開発、(3)NK細胞における最適なシグナルドメインの同定、(4)開発したNK細胞製剤の有用性の証明(in-vitro / ヒト腫瘍の異種移植マウスモデル)、の4項目に沿って研究を進めている。(1)については従来型のフィーダー細胞を用いる培養と複数サイトカインと刺激抗体による培養との比較検討を、複数のドナーについて実施中である。開始年度には、世界情勢の影響によりNK細胞用特殊培地がまったく入手できなくなる事態が生じたが、その間は、本邦で入手できる別培地の評価を行った。(2)膜型サイトカインについてはX遺伝子の膜結合型コンストラクトをデザイン、ベクターを作成、ウイルスベクターにより細胞株やヒトNK細胞に遺伝子導入し、同コンストラクトが膜結合の状態で膜表面にサイトカインXを発現できることを確認した。機能について検討中である。(3)CD3zに加えて4-1BBまたはCD28などの共刺激受容体シグナルドメインを追加することで、CAR-NK細胞の傷害活性の亢進が確認されている。これら以外の共刺激分子の評価のため、NKp44-CARをベースに5つの異なるコンストラクトを作成した。まずはCAR-T細胞における評価中である。ヒト腫瘍検体RNAにおけるNKp44リガンド発現を検討し、発現が確認された。(4)異種腫瘍を生着させたマウスモデルの作成を複数の腫瘍系について行った。ルシフェラーぜによる腫瘍細胞増殖のモニタリングが可能であることを確認した。NK細胞/CAR-NK細胞のIn vivo機能評価を準備した。

    researchmap

  • 安全で有効かつ、いつでも誰でも使えるCAR-NK細胞療法の新規開発

    Grant number:21K07213

    2021.4 - 2024.3

    System name:科学研究費助成事業 基盤研究(C)

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    今村 勝

      More details

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    researchmap

  • Development of NK Cell expansion by a novel membrane-bound chimeric cytokine

    Grant number:18K07259

    2018.4 - 2021.3

    System name:Grants-in-Aid for Scientific Research

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

    Imamura Masaru

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    The purpose of this study is to develop membrane-bound chimeric cytokines to increase NK cells without systemic administration of cytokines that may cause side effects and to realize safe and effective NK cell therapy. First, we generated the construct of hybrid membrane-bound interleukins 15 and 21. Next, we transduced the construct into a tumor cell line, K562 necessary for the expansion of NK cells, and the efficiency of transduction was as high as 85.5%. When we examined the expansion of NK cells transfected with the construct, we found that the expansion was 27-fold after 7 days, but not as expected.

    researchmap

  • Development of Novel Immunotherapy of Cancer: NKp44-based Chimeric Antigen Receptors and Methods for Ex Vivo NK cell Expansion

    Grant number:16K10015

    2016.4 - 2019.3

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

    Imai Chihaya, IMAMURA MASARU, Takachi Takayuki

      More details

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    We have developed novel chimeric antigen receptors (CAR) as well as a novel method for ex vivo natural killer cell (NK) expansion. We tried to optimize methodology to propagate NK cells with a feeder cell line, K562-mb15-41BBL, by changing several parameters, such as culture medium, E/T ratio, timing of irradiation, and additional drugs. We constructed a variety of CARs that utilize immunoglobulin domain of NKp44 receptor as an antigen-binding portion, which were tested for their surface expression and resulting functional diversities. Following completion of construction of 1st generation CAR, we also optimized the structure of 2nd generation 4-1BB-based NKp44-CAR. Primary human T cells or NK cells, transduced with NKp44-based CAR, are able to express the CAR protein on the cell surface, produce cytokines, and exert strong cytotoxic effects against a wide variety of leukemia cells and solid tumor cells.

    researchmap

  • Development of a novel chimeric antigen receptor T cell immunotherapy targeting immune checkpoint molecules

    Grant number:15K09641

    2015.4 - 2018.3

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

    IMAMURA Masaru, TAKACHI Takayuki, IWABUCHI Haruko

      More details

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    The aim of this study was to develop a novel chimeric antigen receptor T cell (CAR-T) immunotherapy targeting immune checkpoint molecules. We constructed several CARs targeting PDL1/L2 (PD1-CAR). We used extracellular domain of PD-1 from human T cell as a ligand binding domain. Various components were used in the hinge, transmembrane and intracellular domain. The CARs was retrovirally transduced into human T cells from healthy donors. PD1-CAR-T cells showed different PD-1 expression by the constructs. We stimulated OS cell line, U2OS with supernatant from co-culture of CAR-T cells and a cell line. This stimulation upregulated PD-1 ligands expression in U2OS. PD1-CAR-T cells showed significant cytotoxicity against U2OS expressing PD-1 ligands. PD1-CAR may be a candidate of a novel therapy for OS, as secondary CAR-T therapy for cancer that evade after first CAR-T cells targeting another molecule.

    researchmap

  • Translational Research on the Use of Genetically Modified HumanNatural Killer Cells for Refractory Leukemia.

    Grant number:21591349

    2009 - 2012

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

    IMAI Chihaya, IMAMURA Masaru, SAKIKO Yoshida, TAKACHI Takayuki

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    Genetic modification and ex vivo expansion of human natural killer cells were investigated in order to overcome cellular resistance of leukemia, with special interests in the following subjects: 1) feasibility and applicability of the method using the peripheral blood (PB) obtained from patients who suffer from relapse after cord blood transplantation (CBT), 2) improvement of the signal transduction of the anti-CD19 chimeric antigen receptors, 3) improvement of NK cell persistence after in vivo infusion. In this study, ex vivo expansion and genetic modification of donor-derived NK cells from the patients’ PB was shown to be feasible in CBT recipients. The donor-derived NK cells from the patients’ PB were able to expand ex vivo, were susceptible to retroviral gene transduction and exerted powerfulcytotoxicity against CD19^+ leukemia cells via anti-CD19-chimeric receptors.

    researchmap

▶ display all

 

Teaching Experience

  • 統合臨床医学

    2024
    Institution name:新潟大学